Generics - Ranbaxy Laboratories, Cardio-vascular

Filter

Popular Filters

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania

19-04-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry

07-03-2012

The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy

06-12-2011

Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact…

CaduetCardio-vascularGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA

01-12-2011

US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Daiichi Sankyo extends reach in Italy, with Ranbaxy to market its products

05-10-2011

The Italian subsidiaries of Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned India-based…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingRanbaxy Laboratories

Back to top